Mild hypothermia enhanced the protective effect of protein therapy with transductive anti-death FNK protein using a rat focal transient cerebral ischemia model

Brain Res. 2012 Jan 9:1430:86-92. doi: 10.1016/j.brainres.2011.10.041. Epub 2011 Nov 3.

Abstract

We previously reported that the protein transduction domain fused FNK (PTD-FNK) protein, which was derived from anti-apoptotic Bcl-xL protein and thereby gained higher anti-cell death activity, has a strong neuroprotective effect on rat focal brain ischemia models. The aim of this study was to investigate the effect of PTD-FNK protein and hypothermia combined therapy on cerebral infarction. Male SD rats were subjected to 120min middle cerebral artery occlusion (MCAO) with intraluminal thread. Rats were divided into 4 groups: 1) 37°C vehicle administration (37V); 2) 37°C PTD-FNK administration (37F); 3) 35°C vehicle administration (35V); and 4) 35°C PTD-FNK administration (35F). PTD-FNK protein was intravenously administered 60min after the induction of MCAO. Hypothermia (35°C) was applied during 120min MCAO. Rats were sacrificed 24h later; infarct volumes were measured, and Bax, Bcl-2, TUNEL and caspase-12 immunostaining was evaluated. There was significant infarct volume reduction in 37F, 35V, and 35F groups compared to 37V. There was also a significant difference between 37F and 35F. This suggests that hypothermia enhanced the effect of PTD-FNK. Similar results were found in neurological symptoms. Caspase-12 and TUNEL staining showed a significant difference between 37F and 35F; however, Bax and Bcl-2 staining failed to show a difference. In this study we showed an additive protective effect of hypothermia on PTD-FNK treatment, and immunohistological results showed that the protective mechanisms might involve the inhibition of apoptotic pathways through caspase-12, but not through Bcl-2.

MeSH terms

  • Animals
  • Apoptosis / genetics
  • Brain Infarction / metabolism
  • Brain Infarction / pathology
  • Brain Infarction / therapy*
  • Caspase 12 / genetics
  • Caspase 12 / therapeutic use
  • Disease Models, Animal
  • Hypothermia, Induced / methods*
  • Ischemic Attack, Transient / metabolism
  • Ischemic Attack, Transient / pathology
  • Ischemic Attack, Transient / therapy*
  • Male
  • Neuroprotective Agents / chemical synthesis
  • Neuroprotective Agents / pharmacology*
  • Protein Serine-Threonine Kinases / genetics
  • Protein Serine-Threonine Kinases / therapeutic use*
  • Rats
  • Rats, Sprague-Dawley
  • Recombinant Fusion Proteins / chemical synthesis
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / pharmacology
  • Tumor Suppressor Proteins
  • bcl-X Protein / genetics
  • bcl-X Protein / therapeutic use*

Substances

  • Bcl2l1 protein, rat
  • Neuroprotective Agents
  • Recombinant Fusion Proteins
  • Tumor Suppressor Proteins
  • bcl-X Protein
  • PLK3 protein, human
  • Protein Serine-Threonine Kinases
  • Casp12 protein, rat
  • Caspase 12